

# Anatomical and visual outcomes in naïve patients with diabetic macular oedema treated with faricimab

Chatzirallis Alexandros, Rennie Christina, Krishnan Radhika

Southampton Eye Unit, University Hospital Southampton, Southampton, UK

**Purpose:** To evaluate the short-term anatomical and visual outcomes of intravitreal faricimab (IVF) in treatment naïve patients with diabetic macular oedema (DMO) in daily clinical practice.

**Methods:** A retrospective observational study was performed on treatment naïve patients with DMO receiving IVF. Data was collected using electronic patient records and informed consent was omitted as this was a retrospective study and all patient data was kept confidential. All patients were treated with a loading dose of five IVF injections, 4 weeks apart. Primary outcome measures were the change in best-corrected visual acuity (BCVA) and in central subfield thickness (CST) one month after the loading dose (i.e. 4 weeks after the 5th injection) of IVF compared to baseline (within one month of initiating IVF). The paired t-test was used to compare the results to baseline, statistical significance was set to 0.05.

**Results:** Participants in the study were 40 treatment naïve patients with DMO, 23 male and 17 female, with a mean age of  $65.1 \pm 12.8$  years. There was a statistically significant improvement in BCVA one month after the last injection ( $0.32 \pm 0.22$  logMAR) compared to baseline ( $0.45 \pm 0.23$  logMAR,  $p=0.019$ ). Additionally, there was a statistically significant decrease in CST one month after the last injection ( $321.0 \pm 88.9$   $\mu\text{m}$ ) compared to baseline ( $467.7 \pm 67.7$   $\mu\text{m}$ ,  $p<0.001$ ). No safety concerns were noted.

## Conclusions:

Short-term real-world clinical data showed that BCVA and CST improved significantly after the loading dose of 5 injections of IVF. Further studies with larger sample size and longer follow-up are needed to evaluate the efficacy and safety of IVF in real-world daily practice. from other intravitreal agents and a longer-term follow-up.

**Conflict of interest:** "All authors DO NOT have a financial interest/arrangement or affiliation with one or more organizations which could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation"

